Repligen Acquires BioLife Solutions in $1.5 Billion Stock-and-Cash Deal
Repligen has agreed to acquire BioLife Solutions for a total enterprise value of approximately $1.5 billion, with 64% paid in Repligen stock and 36% in cash. The deal is expected to expand Repligen's capabilities in the biopharmaceutical industry.
Topics: biotech industry M&A